A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
Trial details
- Registry ID
- NCT06559163
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Obexelimab in Patients With Systemic Lupus ErythematosusNCT06559163 | Zenas BioPharma (USA), LLC | Phase 2 | Active not recruiting | 2026-09-23Actual |
| A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)NCT06564311 | Zenas BioPharma (USA), LLC | Phase 2 | Active not recruiting | 2025-08-28Actual |
| A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseNCT05662241 | Zenas BioPharma (USA), LLC | Phase 3 | Active not recruiting | 2025-11-13Actual |
| A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)NCT05786573 | Zenas BioPharma (USA), LLC | Phase 3 | Active not recruiting | 2026-06-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |